Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi- Institutional Retrospective Study Using a Propensity Score Analysis

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004 Tomohiko.

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Lobe-Specific Lymph Node Dissection as a Standard Procedure in Surgery for Non– Small Cell Lung Cancer: A Propensity Score Matching Study Hiroyuki Adachi,

Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201 Hisao Asamura, MD, Tomoyuki.

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Mediastinal Nodal Involvement in Patients with Clinical Stage I Non–Small-Cell Lung Cancer: Possibility of Rational Lymph Node Dissection Tomohiro Haruki,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database Tetsuya Mizuno, MD, Meinoshin.

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

Boundary between N1 and N2 Lymph Node Descriptors in the Subcarinal Zone in Lower Lobe Lung Cancer: A Brief Report Mitsuhiro Isaka, MD, Haruhiko Kondo,

Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer David M. Guttmann, MD, MTR, Nandita.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial Katsuyuki Kiura,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Does Repeated Lung Resection Provide Long-Term Survival for Recurrent Pulmonary Metastases of Colorectal Cancer? Results of a Retrospective Japanese Multicenter.

Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002 Noriyoshi Sawabata, MD,

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Visceral Pleural Invasion Classification in Non-small Cell Lung Cancer

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Clinical Relevance of Our Multimodality Prognostic Score

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival: Its Implications for the Forthcoming TNM Staging Based on a Large-Scale.

Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in 2004: Demographic and Prognosis Changes Over Decade Noriyoshi Sawabata, MD, PhD, Etsuo.

Disease-Free Interval Length Correlates to Prognosis of Patients Who Underwent Metastasectomy for Esophageal Lung Metastases Satoshi Shiono, MD, Masafumi.

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Visceral Pleural Invasion Classification in Non–Small-Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer:

Presentation transcript:

Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi- Institutional Retrospective Study Using a Propensity Score Analysis Tomoyuki Hishida, MD, Etsuo Miyaoka, PhD, Kohei Yokoi, MD, Masahiro Tsuboi, MD, Hisao Asamura, MD, Katsuyuki Kiura, MD, Kazuhisa Takahashi, MD, Hirotoshi Dosaka-Akita, MD, Hideo Kobayashi, MD, Hiroshi Date, MD, Hirohito Tada, MD, Meinoshin Okumura, MD, Ichiro Yoshino, MD Journal of Thoracic Oncology Volume 11, Issue 9, Pages 1529-1537 (September 2016) DOI: 10.1016/j.jtho.2016.05.014 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 (A) The overall survival (OS) curves of all patients according to the extent of mediastinal dissection (lobe-specific nodal dissection [LSD] versus systematic nodal dissection [SND]). The 5-year OS rate was 84.7% in LSD group and 81.1% in the SND group. (B, C, and D) The OS curves of the patients with pN0 (B), pN1 (C), and pN2 (D) disease according to the extent of mediastinal dissection. Journal of Thoracic Oncology 2016 11, 1529-1537DOI: (10.1016/j.jtho.2016.05.014) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 The overall survival (OS) curves and the 5-year OS rates according to the tumor location and clinical stage (c-stage) (A: upper lobe c-stage I; B: upper lobe c-stage II; C: lower lobe c-stage I; and D: lower lobe c-stage II). In all of the subgroups, the OS curves for lobe-specific nodal dissection (LSD) were not inferior to those for systematic nodal dissection (SND). Journal of Thoracic Oncology 2016 11, 1529-1537DOI: (10.1016/j.jtho.2016.05.014) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 The distribution of propensity score is shown by Kernel density estimates. LSD, lobe-specific nodal dissection; SND, systematic nodal dissection. Journal of Thoracic Oncology 2016 11, 1529-1537DOI: (10.1016/j.jtho.2016.05.014) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Estimated OS curves according to the inverse probability of treatment weighting–adjusted Cox model between the lobe-specific nodal dissection (LSD) and systematic nodal dissection (SND) groups. HR, hazard ratio. Journal of Thoracic Oncology 2016 11, 1529-1537DOI: (10.1016/j.jtho.2016.05.014) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1 Journal of Thoracic Oncology 2016 11, 1529-1537DOI: (10.1016/j.jtho.2016.05.014) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions